Marshall T. Schreeder

Learn More
BACKGROUND Bcl-2 family genes are frequently amplified in small cell lung cancer (SCLC). A phase I trial was conducted to evaluate the safety of obatoclax, a Bcl-2 family inhibitor, given in combination with standard chemotherapy. METHODS Eligible patients (3-6 per cohort) had extensive-stage SCLC, measurable disease, ≤ 1 before therapy, Eastern(More)
INTRODUCTION The addition of taxanes (Ts) to chemotherapeutic regimens has not demonstrated a consistent benefit in early-stage breast cancer. To date, no clinically relevant biomarkers that predict T response have been identified. METHODS A dataset of immunohistochemistry stains in 411 patients was mined to identify potential markers of response. TLE3(More)
Electroencephalography (EEG) in dialysis encephalopathy (DE) was investigated by collecting 173 EEGs from 77 dialyzed patients; 26 had DE. An attempt was made to predict the DE patients, as opposed to the control group without DE, on the basis of EEG alone. Based on the presence or absence of bilateral spike and wave complexes, 91% of the patients along(More)
Ibrutinib is effective in patients with chronic lymphocytic leukaemia (CLL); however, treatment resistance remains a problem. Ublituximab is a novel, glycoengineered anti-CD20 monoclonal antibody with single-agent activity in relapsed CLL. We report the results of a phase 2 study evaluating combination therapy with ibrutinib and ublituximab in patients with(More)
BACKGROUND Over-expression of HER2 in a subset of breast cancers (HER2+) is associated with high histological grade and aggressive clinical course. Despite these distinctive features, the differences in response of HER2+ patients to both adjuvant cytotoxic chemotherapy and targeted therapy (e.g. trastuzumab) suggests that unrecognized biologic and clinical(More)
  • 1